Merck is teaming up with Isomorphic Labs, the Alphabet-owned company specializing in AI-based drug design, to find new cancer drug candidates, the companies announced this week

3

2

1

.

Source: Market Screener

Source: Market Screener

One target, small molecules

The collaboration covers a single cancer target, which the companies describe as of strategic importance but do not name. It looks only for small-molecule drug candidates against it

3

2

1

.

Isomorphic will do the early work on computers, using its own drug design engine, called IsoDDE, to predict and design molecules. That engine will draw on a selection of Merck's proprietary datasets, supplied specifically for this collaboration

3

1

. Everything after that stays with Merck: the New Jersey company keeps preclinical and clinical development, manufacturing and, if a drug emerges, selling it

2

1

.

Source: Silicon Republic

Source: Silicon Republic

The money, and the timing

Isomorphic gets an upfront payment plus milestone payments tied to research, development, regulatory and commercial progress, and tiered royalties on any sales. None of the amounts were disclosed

3

2

. Isomorphic also holds an option to help fund development work in exchange for higher royalties

3

1

.

The deal lands days after Isomorphic announced a $5bn funding round, per Silicon Republic, co-led by Greenoaks and Sequoia Capital with backing from Alphabet, Andreessen Horowitz and existing investors including Thrive Capital and Temasek

1

.

Isomorphic chief research officer Sarah Skerratt said the deal would "unlock significant discovery progress" for patients whose needs current drugs do not meet

1

. George Addona, who runs discovery research at Merck, has said that making AI drug design work depends on close coordination between lab experiments and computer modelling. Pairing Merck's data with Isomorphic's modelling and computing power, he said, aims to produce better drug candidates faster

1

.

© 2026 TheOutpost.AI All rights reserved